Boston Scientific CEO buys 186,240 shares

Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47.

Rhea-AI Filing Summary

Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47. After this open-market buy, he directly owns 1,590,024 shares and indirectly holds 22,119 shares via a 401(k) Retirement Savings Plan following a discretionary rebalancing transaction at $48.4300 per share.

Insider Trade Summary

Net Buyer: 186,240 shares

Net Buy 2 txns

Insider Mahoney Michael F

Role Chairman, President & CEO

Bought 186,240 shs ($9.00M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	186,240	$48.3323	$9.00M
Discretionary	Common Stock F2	22,119	$48.43	$1.07M

Holdings After Transaction: Common Stock — 1,590,024 shares (Direct); Common Stock — 22,119 shares (Indirect, By 401(k))

Footnotes (2)

1. F1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
2. F2. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

Key Figures

Shares purchased (direct): 186240.0000 shares Weighted average purchase price: $48.3323 per share Direct holdings after transaction: 1590024.0000 shares +3 more

6 metrics

Shares purchased (direct) 186240.0000 shares Common Stock purchased on 2026-08-03 in open-market transaction

Weighted average purchase price $48.3323 per share Open-market Common Stock buy with trades from $47.87 to $48.47

Direct holdings after transaction 1590024.0000 shares Directly owned Common Stock following 2026-08-03 purchase

Shares acquired via 401(k) 22119.0000 shares Discretionary rebalancing under 401(k) Retirement Savings Plan

401(k) transaction price $48.4300 per share Price for shares acquired indirectly by 401(k) on 2026-08-03

Net buy shares reported 186240 shares Net buy direction from transaction summary (non-derivative)

Key Terms

weighted average purchase price, discretionary transaction, Rule 16b-3(f), 401(k) Retirement Savings Plan

4 terms

weighted average purchase price financial

"Represents the weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

discretionary transaction regulatory

"resulted in a discretionary transaction in shares of the Company's common stock."

Rule 16b-3(f) regulatory

"Discretionary transaction under Rule 16b-3(f)"

401(k) Retirement Savings Plan financial

"under the Company's 401(k) Retirement Savings Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider purchase did Boston Scientific (BSX) CEO Michael Mahoney report?

Michael Mahoney reported buying 186,240 shares of Boston Scientific common stock on August 3, 2026. The open-market transaction used a $48.3323 weighted average price, with individual trades executed between $47.87 and $48.47 per share.

How many Boston Scientific (BSX) shares does Michael Mahoney hold after these transactions?

After the reported transactions, Michael Mahoney directly holds 1,590,024 shares of Boston Scientific common stock. He also indirectly holds 22,119 shares through the company’s 401(k) Retirement Savings Plan following a discretionary rebalancing election.

At what prices were the Boston Scientific (BSX) shares purchased by the CEO?

The CEO’s open-market purchase used a $48.3323 weighted average price, based on multiple trades from $47.87 to $48.47 per share. A separate 401(k) rebalancing transaction acquired shares at $48.4300 per share.

What is the 401(k) transaction involving Boston Scientific (BSX) shares?

Mahoney acquired 22,119 shares indirectly through a 401(k) Retirement Savings Plan transaction. This resulted from his election to rebalance plan holdings, creating a discretionary transaction in Boston Scientific common stock under the company’s retirement plan.

Were the Boston Scientific (BSX) insider transactions made under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as an affirmative plan. The filing instead describes an open-market purchase and a discretionary 401(k) rebalancing transaction, without identifying them as executed under a 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:16 PM Accepted by SEC EDGAR 08/05/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahoney Michael F

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		186,240	A	$48.3323(1)	1,590,024	D
Common Stock	08/03/2026		I(2)		22,119	A	$48.43	22,119	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

	/s/ Susan Thompson, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)